Drug intelligence / Profile preview

PDI-320

Development stage: Phase 2
Lead developer: Valeant Pharmaceuticals
Modality: Small Molecules
Administration: Topical

Overview

PDI-320 is a small molecule drug initially developed by Bausch Health Americas for dermatological indications, specifically targeting skin and musculoskeletal diseases. Its primary indication has been rosacea, where it reached Phase 2 clinical trials. The precise mechanism of action for PDI-320 remains unknown. The drug was also associated with PreCision Dermatology as an inactive organization in its development history[1][2][3].

Beyond the preview

Go deeper on PDI-320.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PDI-320.

Explore the full profile